The clinical study to evaluate the safety of the regenerative medicine and the gene therapy by the autologous transplantation of human LCAT gene transduced human pre-adipocyte (LCAT-Trial-24 weeks)

未提供0 个研究点目标入组 3 人开始时间: 待定最近更新: 2024年4月24日

试验速览

阶段: 不适用
状态: 招募中
入组人数: 3
主要终点: Appearance of RCR after administration of clinical trial products

研究概览研究设计入排标准结局指标研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional
分配方式: Single Arm Study
干预模型: Single Assignment
主要目的: Treatment Purpose
盲法: Open(masking Not Used)

入排标准

年龄范围: 16age old over 至 No limit（—）
性别: All

入选标准

•Patients who meet all of the following conditions.
•Patients with a definitive diagnosis of familial LCAT deficiency based on the following diagnostic criteria
•(1) LCAT gene mutation has been confirmed in genetic diagnosis (having amino acid residue substitution in LCAT protein)
•(2) Low HDL-cholesterol (less than 25 mg/dL) is observed, and one or some of following complications typical for this disease is detected; corneal opacification, renal dysfunction (proteinuria), hemolytic anemia
•(3) Blood LCAT activity (artificial substrate method) is below the detection limit (reference standard value 382-512U)
•Patients older than
•Patient who provides written informed consent. If the patient is a minor, written consent must be obtained from the patient as well as a parent or guardian.

排除标准

•Patients who meet any of the following conditions are not included.
•Patients who are not expected to express full-length LCAT protein due to frameshift or the appearance of stop codon by insertion/deletion mutation in LCAT gene
•Patients whose mutant LCAT protein cannot be detected in blood by immunological method (ELISA or immunoprecipitation western blot)
•Patients with advanced liver disease (fulminant hepatitis, cirrhosis, etc.) that affects lipid metabolism
•Patients with advanced renal disease (transferred or planned to transfer to dialysis)
•Patients who received LCAT protein replacement therapy by whole blood or plasma transfusion within 1 month before obtaining written consent.
•Patients who are considered to be difficult to perform subcutaneous liposuction
•Pregnant and lactating women. In the case of female patients who can become pregnant (all women except those who have undergone permanent contraception or those who have been postmenopausal*), those who do not agree to contraception during the clinical trial period (up to 24 weeks after administration). In addition, in the case of male patients, patients who do not agree to contraception during the clinical trial period (up to 24 weeks after administration).
•Patients with other similar diseases that are not caused by LCAT deficiency and have low HDL-cholesterol (Apo A-1 abnormality/Tangier disease)
•Patients with a history of hypersensitivity to the components of this clinical trial product or the components (fetal bovine serum and human albumin) used in the manufacturing process of this clinical trial product.
•Other patients who are deemed unsuitable by the investigator or the sub-investigator

结局指标

主要结局

Appearance of RCR after administration of clinical trial products

Tumorigenesis of the administration site after administration of the clinical trial product

Tumorigenesis of the administration site after administration of the clinical trial product (complementarily evaluated by the following 2 items) (A) MRI examination (B) Tumorigenicity test of the clinical trial product in immunodeficient (NSG) mice

Appearance of anti-LCAT antibody after administration of clinical trial products

Occurrence of unexpected serious adverse events other than (1) to (3)

次要结局

Type, frequency and severity of adverse events
LCAT activity(during the observation period)
Blood LCAT concentration(during the observation period)

研究者

发起方

未提供

相似试验

招募中

1 期

The clinical study to evaluate the safety of the regenerative medicine and the gene therapy by the autologous transplantation of human LCAT gene transduced human pre-adipocyteFamilial LCAT deficiencyCorneal opacity, Renal dysfunction, Hemolytic anemiaD007863

JPRN-jRCT2033200096Yokote Koutaro3

进行中（未招募）

不适用

Clinical Trial for the Evaluation of the Safety of the Product in Study Cream Gel through the Evaluation of Skin Compatibility under Normal Conditions of UseHypersensitivityN06.850.210

RBR-8fnb6xxKosmosciense Ciência e Tecnologia Cosm Imp Exp Ltda

已完成

2 期

A clinical of Appetol syrup in children suffering from non-specific anorexia (loss of appetite)

CTRI/2014/07/004756ARJUN HEALTHCARE50

招募中

3 期

Clinical trial of Lipidil Tablet in comparison with Atorvastatin in patients with abnormal amount of lipids.

CTRI/2014/09/005015Arjun Healthcare80

已完成

2 期

A clinical trial to study the effect of AHPL/AYTAB/0313 in patients suffering from arthritis of knee(s)

CTRI/2015/09/006177Ari Healthcare Pvt Ltd48